Methods for Treating Gout Flares
Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
1 .- 18 . (canceled)
19 . A method for decreasing the number, duration, frequency, or intensity of gout flares experienced by a subject during initiation or maintenance of therapy for the disappearance or reduction of tophi, comprising administration to the subject of a therapeutically effective amount of a flare decreasing agent that is selected from the group consisting of (−)-halofenate and (−)-halofenic acid, or a pharmaceutically acceptable salt thereof, and substantially free from the corresponding (+)-enantiomer.
20 . The method of claim 19 where the flare decreasing agent is (−)-halofenate.
21 . The method of claim 197 where the flare decreasing agent is (−)-halofenic acid or a pharmaceutically acceptable salt thereof.
22 . The method of claim 19 where the therapeutically effective amount of the flare decreasing agent is between about 50 mg/day and about 1000 mg/day.
23 . The method of claim 22 where the therapeutically effective amount of the flare decreasing agent is between about 400 mg/day and about 1000 mg/day.
24 . The method of claim 23 where the therapeutically effective amount of the flare decreasing agent is 400, 600, or 800 mg/day.
25 . The method of claim 19 further comprising concomitant administration to the subject of a therapeutically effective amount of a flare prophylaxis agent or a pain management agent.
26 . The method of claim 25 , where the concomitant administration comprises concurrent administration of the flare decreasing agent and the flare prophylaxis agent or pain management agent.
27 . The method of claim 25 where the concomitant administration comprises sequential administration of the flare decreasing agent and the flare prophylaxis agent or pain management agent.
28 . The method of claim 25 where the flare decreasing agent is (−)-halofenate.
29 . The method of claim 25 where the flare decreasing agent is (−)-halofenic acid or a pharmaceutically acceptable salt thereof.
30 . The method of claim 25 where the therapeutically effective amount of the flare decreasing agent is between about 50 mg/day and about 1000 mg/day.
31 . The method of claim 30 where the therapeutically effective amount of the flare decreasing agent is between about 400 mg/day and about 1000 mg/day.
32 . The method of claim 31 where the therapeutically effective amount of the flare decreasing agent is 400, 600, or 800 mg/day.
33 . The method of claim 25 where the flare prophylaxis agent or pain management agent is an NSAID, an opiate, or colchicine.
34 . The method of claim 33 where the flare prophylaxis agent or pain management agent is colchicine.